poisar

Stocks · News reference

Lipocine Announces First Patient Dosed In Phase 3 BLOOM Trial Of LPCN 1154 In Postpartum Depression; Expects Topline Data In 2H 2027

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Lipocine Inc. (LPCN)

    Filed: 2026-11-10 AccNo: 0001493152-26-050842 Size: 239 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits